vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Grand Canyon Education, Inc. (LOPE). Click either name above to swap in a different company.
Grand Canyon Education, Inc. is the larger business by last-quarter revenue ($308.1M vs $196.0M, roughly 1.6× Axsome Therapeutics, Inc.). Grand Canyon Education, Inc. runs the higher net margin — 28.1% vs -14.6%, a 42.7% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 5.3%). Grand Canyon Education, Inc. produced more free cash flow last quarter ($122.9M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 5.9%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Grand Canyon Education, Inc. (GCE) is an American for-profit corporation that provides services to universities, specializing in program development, online education, and operational support. Formerly affiliated with Grand Canyon University (GCU), a Christian university in Arizona, GCE became a separate publicly traded company in 2008.
AXSM vs LOPE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $308.1M |
| Net Profit | $-28.6M | $86.7M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | 35.1% |
| Net Margin | -14.6% | 28.1% |
| Revenue YoY | 65.0% | 5.3% |
| Net Profit YoY | 61.9% | 5.9% |
| EPS (diluted) | $-0.55 | $3.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $308.1M | ||
| Q3 25 | $171.0M | $261.1M | ||
| Q2 25 | $150.0M | $247.5M | ||
| Q1 25 | $121.5M | $289.3M | ||
| Q4 24 | $118.8M | $292.6M | ||
| Q3 24 | $104.8M | $238.3M | ||
| Q2 24 | $87.2M | $227.5M | ||
| Q1 24 | $75.0M | $274.7M |
| Q4 25 | $-28.6M | $86.7M | ||
| Q3 25 | $-47.2M | $16.3M | ||
| Q2 25 | $-48.0M | $41.5M | ||
| Q1 25 | $-59.4M | $71.6M | ||
| Q4 24 | $-74.9M | $81.9M | ||
| Q3 24 | $-64.6M | $41.5M | ||
| Q2 24 | $-79.3M | $34.9M | ||
| Q1 24 | $-68.4M | $68.0M |
| Q4 25 | -13.8% | 35.1% | ||
| Q3 25 | -27.0% | 6.9% | ||
| Q2 25 | -24.5% | 20.9% | ||
| Q1 25 | -46.9% | 30.4% | ||
| Q4 24 | -61.1% | 34.2% | ||
| Q3 24 | -59.8% | 20.2% | ||
| Q2 24 | -89.5% | 18.8% | ||
| Q1 24 | -89.7% | 30.8% |
| Q4 25 | -14.6% | 28.1% | ||
| Q3 25 | -27.6% | 6.2% | ||
| Q2 25 | -32.0% | 16.8% | ||
| Q1 25 | -48.9% | 24.8% | ||
| Q4 24 | -63.1% | 28.0% | ||
| Q3 24 | -61.7% | 17.4% | ||
| Q2 24 | -91.0% | 15.3% | ||
| Q1 24 | -91.1% | 24.8% |
| Q4 25 | $-0.55 | $3.13 | ||
| Q3 25 | $-0.94 | $0.58 | ||
| Q2 25 | $-0.97 | $1.48 | ||
| Q1 25 | $-1.22 | $2.52 | ||
| Q4 24 | $-1.54 | $2.83 | ||
| Q3 24 | $-1.34 | $1.42 | ||
| Q2 24 | $-1.67 | $1.19 | ||
| Q1 24 | $-1.44 | $2.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $111.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $746.9M |
| Total Assets | $689.8M | $992.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $111.8M | ||
| Q3 25 | $325.3M | $97.3M | ||
| Q2 25 | $303.0M | $192.3M | ||
| Q1 25 | $300.9M | $144.5M | ||
| Q4 24 | $315.4M | $324.6M | ||
| Q3 24 | $327.3M | $263.6M | ||
| Q2 24 | $315.7M | $241.3M | ||
| Q1 24 | $331.4M | $196.2M |
| Q4 25 | $88.3M | $746.9M | ||
| Q3 25 | $73.7M | $758.0M | ||
| Q2 25 | $73.1M | $778.0M | ||
| Q1 25 | $53.2M | $780.7M | ||
| Q4 24 | $57.0M | $783.9M | ||
| Q3 24 | $92.9M | $764.1M | ||
| Q2 24 | $102.9M | $759.2M | ||
| Q1 24 | $144.0M | $759.4M |
| Q4 25 | $689.8M | $992.3M | ||
| Q3 25 | $669.3M | $1.0B | ||
| Q2 25 | $639.8M | $1.0B | ||
| Q1 25 | $596.7M | $1.0B | ||
| Q4 24 | $568.5M | $1.0B | ||
| Q3 24 | $561.5M | $992.9M | ||
| Q2 24 | $548.2M | $992.7M | ||
| Q1 24 | $545.7M | $1.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $130.5M |
| Free Cash FlowOCF − Capex | $-18.7M | $122.9M |
| FCF MarginFCF / Revenue | -9.6% | 39.9% |
| Capex IntensityCapex / Revenue | 0.0% | 2.5% |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $238.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $130.5M | ||
| Q3 25 | $1.0M | $-48.6M | ||
| Q2 25 | $-32.4M | $124.0M | ||
| Q1 25 | $-43.4M | $67.6M | ||
| Q4 24 | $-26.2M | $135.8M | ||
| Q3 24 | $-18.6M | $-29.4M | ||
| Q2 24 | $-30.1M | $98.6M | ||
| Q1 24 | $-53.5M | $85.0M |
| Q4 25 | $-18.7M | $122.9M | ||
| Q3 25 | $988.0K | $-58.3M | ||
| Q2 25 | $-32.4M | $115.4M | ||
| Q1 25 | $-43.7M | $58.7M | ||
| Q4 24 | $-26.2M | $126.1M | ||
| Q3 24 | $-18.7M | $-39.0M | ||
| Q2 24 | $-30.2M | $89.6M | ||
| Q1 24 | $-53.6M | $76.0M |
| Q4 25 | -9.6% | 39.9% | ||
| Q3 25 | 0.6% | -22.3% | ||
| Q2 25 | -21.6% | 46.6% | ||
| Q1 25 | -36.0% | 20.3% | ||
| Q4 24 | -22.1% | 43.1% | ||
| Q3 24 | -17.9% | -16.3% | ||
| Q2 24 | -34.6% | 39.4% | ||
| Q1 24 | -71.4% | 27.7% |
| Q4 25 | 0.0% | 2.5% | ||
| Q3 25 | 0.0% | 3.7% | ||
| Q2 25 | 0.0% | 3.5% | ||
| Q1 25 | 0.3% | 3.1% | ||
| Q4 24 | 0.0% | 3.3% | ||
| Q3 24 | 0.1% | 4.0% | ||
| Q2 24 | 0.1% | 3.9% | ||
| Q1 24 | 0.1% | 3.3% |
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | -2.99× | ||
| Q2 25 | — | 2.98× | ||
| Q1 25 | — | 0.94× | ||
| Q4 24 | — | 1.66× | ||
| Q3 24 | — | -0.71× | ||
| Q2 24 | — | 2.83× | ||
| Q1 24 | — | 1.25× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
